Big Savings for Biosimilars?

As costs for complex new biologic specialty drugs continue to soar, insurers, PBM’s and other payers are looking to biosimilars for price relief. Many hope that biosimilars will provide less-expensive versions of branded biologic drugs in the same way generic drugs do for small-molecule chemical drugs.

Watch this on-demand webinar and hear from experts on the current state of biosimilars, what’s coming to the market and some of the challenges in store.